Collegium Pharmaceutical First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Collegium Pharmaceutical (NASDAQ:COLL) First Quarter 2025 Results

Key Financial Results

• Revenue: US$177.8m (up 23% from 1Q 2024).
• Net income: US$2.42m (down 91% from 1Q 2024).
• Profit margin: 1.4% (down from 19% in 1Q 2024).
• EPS: US$0.076 (down from US$0.86 in 1Q 2024).

Our free stock report includes 4 warning signs investors should be aware of before investing in Collegium Pharmaceutical. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Collegium Pharmaceutical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 70%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 4.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Collegium Pharmaceutical (of which 1 is a bit unpleasant!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.